REGENECORE Annual Ceremony | Unity, Innovation, and Win the FutureTime of issue : 2024- 01-31
On January 18th, the theme annual meeting of "Unity, Innovation, and Win Win Future" of REGENECORE was successfully held in Nanjing, with the participation of all employees of the company.
All employees of REGENECORE carry out the Red Party Building Activity in the Ta-pieh MountainsTime of issue : 2023- 08-23
All employees of REGENECORE went to the Dabie Mountains to carry out the red party building activity of "Rewalking the Long March Road and Advancing a New Journey".
REGENECORE is the world's first IL4Rα-IL5 double antibody completed the first subject administrationTime of issue : 2023- 07-07
REGENECORE antibody drugs development enter the clinical research stage
REGENECORE RC1416 Injection Approved for Clinical Trial Application in the United StatesTime of issue : 2023- 04-21
Recently, Nanjing RegeneCore Biotech Co.,Ltd(hereinafter referred to as RegeneCore), a subsidiary of YOUNGY GROUP, independently developed the bispecific nanobody drug RC1416 injection, which has been approved for clinical trials by the US Food and Drug Administration (FDA), marking the synchronization of the product's clinical development strategy with the international market.